United States – Page 3

Federal Judge Blocks NIH Grant Caps as HHS Appeals Ruling

4 months ago talkbio0Tagged Administration occupational activities, Administrative Procedure Act, appeal, CHARGE Syndrome, federal judge, Health Policy, Indirect, injunction, Legal, Medical Research activity, NIH Mouse, Permanent, research, Transplant Registry Unified Management Program, U.S., United States

NIH, HHS, research funding, grant caps, indirect costs, federal judge, permanent injunction, Trump administration, medical research, Administrative Procedure Act, legal appeal, U.S. healthcare policy.

Trump Announces Imminent Major Tariffs on Pharmaceuticals: Implications for Global Markets and U.S. Manufacturing

4 months ago talkbio0Tagged drug price, Impact food supplement, Pharma import taxes, pharmaceutical manufacturing, Pharmaceutical stocks, pharmaceutical tariffs, Policy, Relations, TNFRSF19 gene, Transplant Registry Unified Management Program, U.S.-China, United States

Trump pharmaceutical tariffs, U.S. pharmaceutical manufacturing, Pharma import taxes, Drug price impact, Trade policy 2025, U.S.-China trade relations, Pharmaceutical stocks

U.S. Congressional Report Calls for $15 Billion to Bolster Biotech Leadership Amid Rising Chinese Competition

4 months ago talkbio0Tagged Bioeconomy, Biomanufacturing Strategy, Biotech Competition, Biotechnology, Biotechnology Advantage, China, Investments, National Security Commission, Tech Rivalry, U.S.-China, United States

U.S. Biotechnology Advantage, China Biotech Competition, National Security Commission on Emerging Biotechnology, Biotechnology Investment, Biomanufacturing Strategy, U.S.-China Tech Rivalry, Bioeconomy

Trump Tariffs Poised to Hit Drug Tool and Packaging Manufacturers: Industry Faces Rising Costs and Supply Chain Challenges

4 months ago talkbio0Tagged alpha 1-antitrypsin, Biopharma trade war, Drug Industry, Drug packaging industry, Generic Drugs, Impact food supplement, lobbying, Manufacturing, Market, onshoring, Pharmaceutical Supply Chain, pharmaceutical tariffs, Supply chain disruption, Trump tariffs, U.S., United States

Trump tariffs , Drug packaging industry , Pharmaceutical supply chain , API manufacturing costs , Biopharma trade war , U.S. manufacturing onshoring , Generic drugs market impact , Pharmaceutical tariffs , Supply chain disruption , Pharmaceutical industry lobbying

Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing and Innovation

4 months ago talkbio0Tagged aligns, announcement, Benefit, capabilities, commitment, Corporation, domestic pharmaceutical industry, Increased, innovation, Investments, J&J 's, Manufacturing, Surgical construction, trends qualifier, United States

This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.

Corrected: Merck opens billion-dollar US facility to make Gardasil

4 months ago talkbio0Tagged Facility (object), Gardasil, Merck, Merck 's, United States, Vaccines

Merck, Gardasil, Facility (object), Vaccines, Merck ‘s, United States

In an unusual move, Lilly seeks pitches from US states for slice of $27B buildout

5 months ago talkbio0Tagged Eli Lilly, Investments, Lilly 's, United States

Eli Lilly, Investments, United States, Lilly ‘s

WuXi AppTec Faces Uncertainty Amid BIOSECURE Act, Yet Continues to Secure New Projects

9 months ago talkbio0Tagged AppTec, Biopharma, BIOSECURE, CDMOs, Contract agreement, Industry, Legislation, manufacturing organizations, National Security Concerns, Outsourcing, United States, WuXi

BIOSECURE Act, WuXi AppTec, Biotechnology Industry, U.S. Legislation, Contract Development and Manufacturing Organizations (CDMOs), Biopharma Outsourcing, National Security Concerns

BIOSECURE Act: Navigating Industry Implications and Future Directions

10 months ago talkbio0Tagged BIOSECURE, Biotechnology, capabilities, CDMOs, Chinese Language, Contract agreement, development aspects, Industry, Manufacture, manufacturing organizations, pharmaceutical imports, Pharmaceutical supply chain resilience, Supply chain disruptions, United States

BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience

BIOSECURE Act Clears House Hurdle, Heads to Senate for Vote on Restricting Chinese Biotech Ties

11 months ago talkbio0Tagged BIOSECURE, Biotech Companies, Biotechnology, Chinese Language, Drug Industry, drug supply chain, innovation, National Security, Risk, Senate, United States, US House of Representatives, Voting

BIOSECURE Act, House of Representatives, Senate Vote, Chinese Biotech Companies, National Security Risks, U.S. Pharmaceutical Industry, Biotechnology Innovation, Drug Supply Chain